Skip to Content
Søg Menu
Vi dækker

ESMO I European Society for Medical Oncology

ESMO 2025

ESMO_kongresside

  • / marie

Artikler fra ESMO 2025

MEDtalks fra ESMO 2025

ESMO 2024

ESMO_kongresside

  • / marie

ESMO_kongresside

/ marie

Highlights fra ESMO 2024

Louise Wichmann Matthiessen

Highlights: Det kliniske landskab for brystkræft efter ESMO 2024

/ Louise Wichmann Matthiessen
ESMO24Brystcancer Play the Video
Dag Rune Stormoen

Highlights fra ESMO 2024: Non-muskelinvasiv, muskelinvasiv og metastatisk / lokal-avanceret blærecancer

/ Dag Rune Stormoen
ESMO24Blærecancer Play the Video
Morten Mau-sørensen

Highlights fra ESMO 2024 for øvre gastrointestinal cancer

/ Morten Mau-Sørensen
ESMO24Gastrointestinal cancer Play the Video
Jens Benn Sørensen

Highlights fra ESMO 2024 om lungecancer

/ Jens Benn Sørensen
ESMO24Lungecancer Play the Video
Charlotte Aa. Hasund

ESMO 2024: Highlights for ovariecancer og endometricancer

/ Charlotte Haslund
ESMO24Gynækologisk cancer Play the Video
Rasmus Friis

Fejring af langtidsdata for behandling af metastatisk malign melanom – og døren til neoadjuverende behandling er ved at åbne sig

/ Rasmus Blechingberg Friis
ESMO24Melanom Play the Video

Top 4 mest sete MEDtalks fra ESMO 2024

Abstracts fra ESMO 2024

ESMO_kongresside

  • / marie

ESMO 2023 • Meet the experts

Get access

ESMO 2022

Endocrine Response for Routine Decision-making on Chemotherapy use in HR+/HER2-N0-1 Early Breast Cancer

/ Onkologi / Nadia Harbeck

Current landscape in the immuno-oncology treatment of non-melanoma skin cancers

/ Onkologi / Paolo Antonio Ascierto

Sexual health in long-term breast cancer survivors

/ Onkologi / Solveig Katrine Smedsland

ICON trial update: Ipi+Nivo combination with chemotherapy does not improve survival

/ Onkologi / Jon Amund Kyte

The clinical value of circulating tumor DNA in bladder and renal cancer

/ Onkologi / Lars Dyrskjøt Andersen
Se oversigt

Outstanding results of ovarian cancer treatment

/ Onkologi / Clare Scott

Optimizing the front-line PARP-inhibitor treatment of ovarian cancer from a Nordic perspective

/ Onkologi / Kristina Lindemann

Efficacy of trastuzumab-deruxtecan therapy in HER2-positive breast cancer

/ Onkologi / Angelika Starzer

ESMO Highlights: Promising data for the frontline treatment of gynecologic cancer

/ Onkologi / Kristina Lindemann

ESMO Highlights: Increase awareness of supportive and palliative care for patients with cancer

/ Onkologi / Christina H. Ruhlmann
Se oversigt

ESMO Highlights: Practical changes for treatment of lower gastrointestinal tumors

/ Onkologi / Marco Gerlinger

First-line atezolizumab treatment significantly improves overall survival in patients with NSCLC and not eligible for a platinum-containing regimen

/ Onkologi / Siow Ming Lee

Klinik for senfølger efter kræft: 80% af de besøgende er kvinder

/ Almen praksis / Karin Dieperink

COSMIC-313 – the first metastatic renal cell carcinoma (RCC) phase 3 trial with a doublet nivolumab plus ipilimumab

/ Onkologi / Toni K. Choueiri

Overraskende resultater ved aktiv brug af PRO under behandling af blærecancer

/ Onkologi / Gry Assam Taarnhøj
Se oversigt

ESMO 2021

Back to top